Form 8-K - Current report:
SEC Accession No. 0001213900-25-063277
Filing Date
2025-07-11
Accepted
2025-07-11 16:15:58
Documents
13
Period of Report
2025-07-10
Items
Item 5.08: Shareholder Nominations Pursuant to Exchange Act Rule 14a-11

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0248679-8k_pasithea.htm   iXBRL 8-K 27403
  Complete submission text file 0001213900-25-063277.txt   238800

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE ktta-20250710.xsd EX-101.SCH 3809
3 XBRL DEFINITION FILE ktta-20250710_def.xml EX-101.DEF 26680
4 XBRL LABEL FILE ktta-20250710_lab.xml EX-101.LAB 36818
5 XBRL PRESENTATION FILE ktta-20250710_pre.xml EX-101.PRE 25304
15 EXTRACTED XBRL INSTANCE DOCUMENT ea0248679-8k_pasithea_htm.xml XML 5937
Mailing Address 1111 LINCOLN ROAD, SUITE 500 MIAMI BEACH FL 33139
Business Address 1111 LINCOLN ROAD, SUITE 500 MIAMI BEACH FL 33139 (702) 514-4174
Pasithea Therapeutics Corp. (Filer) CIK: 0001841330 (see all company filings)

EIN.: 851591963 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40804 | Film No.: 251119168
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)